Trial
NCT01981811
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
—
Condition
Bipolar 1 Disorder
Intervention
Aripiprazole
Why stopped
The trial was terminated because it was determined that the usability of the MIND1 System in the intended population was necessary before conducting this trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-28